# IGF-1 LR3 dosage & reconstitution (1 mg vial)

IGF-1 LR3 dosage: calculations for a 1 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 1 mg/mL, so each U-100 unit contains 10 mcg.

- **Vial contents:** 1 mg IGF-1 LR3
- **Final volume:** 1 mL
- **Concentration:** 1 mg/mL
- **One U-100 unit:** 10 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (1 mL = ~1 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg | 2 units (0.02 mL) |
| Weeks 3–4 | 40 mcg | 4 units (0.04 mL) |
| Weeks 5–8 | 50 mcg | 5 units (0.05 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 1 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 20 mcg | 50 injections |
| 5 | 0.05 mL | 50 mcg | 20 injections |
| 10 | 0.10 mL | 100 mcg | 10 injections |
| 20 | 0.20 mL | 200 mcg | 5 injections |
| 30 | 0.30 mL | 300 mcg | 3 injections |
| 50 | 0.50 mL | 500 mcg | 2 injections |
| 100 | 1.00 mL | 1 mg (1000 mcg) | 1 injection |

## Supplies Needed

**IGF-1 LR3 vials (1 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 4 vials (3.64 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 8 vials (7.84 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 4 mL total (1 mL per vial) → 2 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 8 mL total (1 mL per vial) → 3 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

IGF-1 LR3 (Long-R3 Insulin-like Growth Factor 1) is a synthetic analog of human IGF-1 described in the literature as an 83-amino-acid peptide (MW ~9,200 Da) that combines two strategic modifications: Documented molecular modifications: Arg³ substitution → reduced affinity for IGFBP-3/IGFBP-5 binding proteins documented in biochemical studies 13-amino-acid N-terminal extension derived from porcine growth hormone Extended plasma half-life described in the literature (~20-30 hours vs. 12-15 min native IGF-1) Affinities for the IGF-1 receptor are conserved in in vitro models. Signaling pathways described in the literature: IGF-1R Receptor (tyrosine kinase): IRS-1/IRS-2 activation documented in biochemical studies PI3K/Akt/mTORC1 cascade reported as the main protein synthesis pathway MAPK/ERK1/2 associated with cell proliferation in the literature Reported cellular mechanisms (preclinical): Muscle satellite cell activation (Pax7+/MyoD+) in murine models FOXO inhibition/proteolytic atrophy documented in in vitro studies GLUT4-mediated glucose uptake in myocytes described in the literature

---
Source: https://protocolopeptidos.com/en/compuestos/igf-1-lr3-1mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.